Pharmaceutical Stability: Scientific and Regulatory Considerations for Global Drug Development and Commercialization - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Stability: Scientific and Regulatory Considerations for Global Drug Development and Commercialization
A two-day workshop on the "science behind pharmaceutical stability" was held in conjunction with the Annual Meeting of American Association of Pharmaceutical Scientists (AAPS) on Oct. 21-22, 2011 in Washington, DC.




Dissolution failure and failure mode analysis of a Hot melt extrusion product – a case study

Saji Thomas, M. Sc.

The regulatory guidance and the CFR requirements were discussed as an introduction to the main theme of the talk. The high lights of the Barr decision along with FDA’s Guidance on investigating OOS results for pharmaceutical products were discussed. Determining root cause and establishing CAPA is the key to successful OOS investigation. Failure mode analysis tool like Fish bone diagram was discussed as a mean to identify the root cause. The step by step investigation of a dissolution failure of a melt extrusion product was discussed as case study. The product failed at 6 months at accelerated stability condition. Since the initial investigation did not result in identifying the root cause it was decided to evaluate the robustness of the method. A five factorial/eight experiment design was used to evaluate the robustness of the method. The method was found to be very sensitive to the salt added in the dissolution media. A normal probability plot was used to assess robustness of the method using the data generated from the DOE.

Other analytical techniques had to be used since the evaluation of the method did not conclusively prove the root cause of the failure. The product was analyzed using Solid state NMR, Environmental electron scanning microscope, time of flight-secondary ion mass spectroscopy (TOF-SIMS). Products cured at 50c were used for the analysis. SSNMR analysis showed that stearyl alcohol in the formulation if behaving differently after curing the product. A white coating on the product was observed when the product was viewed in an ESEM. The white coating was identified to be stearyl alcohol by TOF-SIMS.

Based on a scientific investigation it was concluded that the dissolution failure was due to the stearyl alcohol migrating to the surface of the product when exposed to heat.

Stability Testing to Support Distribution of Temperature Sensitive Pharmaceuticals

Robert H. Seevers, Ph.D.

All drugs are, to some extent, temperature sensitive. Stability testing makes it possible to determine the appropriate long term storage condition and to evaluate the risk to product quality posed by exposure to temperatures outside that condition. The ICH stability guidances primarily focused on storage conditions and shelf lives for drug substances and drug products. This presentation discussed the other types of testing which may be done in addition to the standard ICH conditions that permit a stability budget to be created for a pharmaceutical.

A stability budget is created using data from long term and accelerated testing such as that provided for in the ICH guidances, but adds freeze-thaw and temperature cycling studies to create a fuller picture of a drug’s susceptibility to changes in temperature that it may experience during the entire distribution process from manufacture to transport, to storage, to end use. The concept of time out of refrigeration has been used to allow for room temperature operations such as packaging and labeling on refrigerated products. This presentation showed how this concept can be expanded to the entire distribution process.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here